Last reviewed · How we verify
Adjuvanted Quadrivalent Influenza Vaccine
This vaccine induces an immune response against multiple strains of influenza.
This vaccine induces an immune response against multiple strains of influenza. Used for Prevention of influenza disease caused by four different strains of the influenza virus.
At a glance
| Generic name | Adjuvanted Quadrivalent Influenza Vaccine |
|---|---|
| Also known as | Fluad® |
| Sponsor | ModernaTX, Inc. |
| Drug class | Influenza vaccine |
| Modality | Biologic |
| Therapeutic area | Immunology |
| Phase | Phase 2 |
Mechanism of action
The vaccine contains four different influenza strains, each with a specific antigen that triggers an immune response. This immune response helps the body to recognize and fight off the influenza virus, reducing the risk of infection.
Approved indications
- Prevention of influenza disease caused by four different strains of the influenza virus
Common side effects
- Pain, redness, or swelling at the injection site
- Fatigue
- Headache
Key clinical trials
- Influenza Vaccination Strategy for Patients With Hematologic Malignancy (PHASE3)
- A Clinical Study to Evaluate the Efficacy, Safety and Immunogenicity of an Adjuvanted Influenza Vaccine Compared to a Non-adjuvanted Influenza Vaccine in Adults ≥65 Years of Age (PHASE3)
- A Study of Modified mRNA Vaccines in Healthy Adults (PHASE1)
- Immunogenicity and Safety Study of Self-amplifying mRNA COVID-19 Vaccine Administered With Influenza Vaccines in Adults (PHASE3)
- A Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1010 in Healthy Adults (PHASE2)
- Safety and Immunogenicity First-in-human Dose-ranging Study of Self-Amplifying RNA Seasonal Influenza Vaccine in Adults (PHASE1)
- Systems Investigation of Vaccine Responses in Aging and Frailty (PHASE2)
- Clinical Trial to Evaluate the Immunogenicity of an Adjuvanted Influenza Vaccine Among HCP (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Adjuvanted Quadrivalent Influenza Vaccine CI brief — competitive landscape report
- Adjuvanted Quadrivalent Influenza Vaccine updates RSS · CI watch RSS
- ModernaTX, Inc. portfolio CI